Foghorn Therapeutics (FHTX) Current Assets (2019 - 2026)

Foghorn Therapeutics' Current Assets history runs 8 years deep, the most recent figure standing at $188.1 million for Q1 2026.

• On a quarterly basis, Current Assets fell 16.57% year-over-year to $188.1 million in Q1 2026; TTM through Mar 2026 was $188.1 million, a 16.57% decrease from a year earlier, with the FY2025 full-year figure at $163.2 million, down 34.6% from the prior year.
• Current Assets grew to $188.1 million in Q1 2026 per FHTX's latest filing, from $163.2 million in the prior quarter.
• Across five years, Current Assets topped out at $429.8 million in Q1 2022 and bottomed at $163.2 million in Q4 2025.
• The 5-year median for Current Assets is $265.4 million (2023), against an average of $274.3 million.
• Across the five-year window, Current Assets surged 204.76% in 2022 and slumped 34.6% in 2025, its largest moves.
• Year by year, Current Assets stood at $351.4 million in 2022, then tumbled by 31.65% to $240.2 million in 2023, then advanced by 3.92% to $249.6 million in 2024, then slumped by 34.6% to $163.2 million in 2025, then increased by 15.21% to $188.1 million in 2026.
• Per Business Quant, the three latest FHTX Current Assets figures stand at $188.1 million (Q1 2026), $163.2 million (Q4 2025), and $184.1 million (Q3 2025).